Lupin has always been very shy in discussing their drug discovery pipeline. However, in an exclusive interview with CNBC-TV18, Dr Kamal Sharma, said that the company is excited about the R&D pipeline, which has 10 lead molecules, and could be potential out-licencing targets by next year.